Proteomic plasma biomarkers for predicting response and resistance with immune checkpoint inhibitors in cancer patients
This study, carried out in collaboration with the Massachusetts General Hospital Cancer Center, performed deep proteomic profiling together with single-cell RNAseq in a metastatic melanoma cohort during Immune Checkpoint Blockade (ICB) treatment.
Initial study: >700 proteins using Olink Target 96 panels
Extended study: ~1500 proteins with the Olink Explore 1536 platform in an extended melanoma cohort comprising 200 patients
Results demonstrate the utility of blood-based protein biomarkers to predict treatment response
Learn more about how Olink® solutions for high-throughput proteomics can accelerate oncology research and drive new therapies
Access interactive functions to explore this unique dataset, including differential expression analysis, pathway enrichment, pathway annotation with hexagonal maps, and predictive protein groups identified by machine learning.
Learn how Olink’s solutions for protein biomarker discovery are being applied in this critical and rapidly developing field, providing non-invasive insights into what is happening in the tumor microenvironment to monitor and predict treatment responses.
Measure the concentration of thousands of human plasma proteins using minute amounts of sample with our high-throughput protein biomarker discovery platform based on Olink’s Proximity Extension Assay (PEA) technology coupled with NGS readout on Illumina instruments.